TY  - GEN 
AU  - Barbarot, S.
AU  - Wollenberg, A.
AU  - Silverberg, J. I.
AU  - Deleuran, M.
AU  - Pellacani, G.
AU  - Armario Hita, José Carlos
AU  - Chen, Z.
AU  - Shumel, B.
AU  - Eckert, L.
AU  - Gadkari, A.
AU  - Lu, Y.
AU  - Rossi, B.
A4  - Medicina
PY  - 2020
SN  - 0954-6634
SN  - 1471-1753 (internet)
UR  - http://hdl.handle.net/10498/23433
AB  - Background:Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several...
LA  - eng
PB  - TAYLOR & FRANCIS LTD
KW  - Adults
KW  - atopic dermatitis
KW  - dupilumab
KW  - SCORAD
TI  - Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials
DO  - 10.1080/09546634.2020.1750550
ER  -